ILMN - Illumina, Inc.
| Previous Close | 322.06 |
| Open | 321.96 |
| Bid | 308.17 x 1200 |
| Ask | 320.23 x 800 |
| Day's Range | 314.00 - 322.44 |
| 52 Week Range | 231.52 - 372.61 |
| Volume | 907,023 |
| Avg. Volume | 956,095 |
| Market Cap | 46.205B |
| Beta (3Y Monthly) | 1.44 |
| PE Ratio (TTM) | 56.57 |
| EPS (TTM) | 5.56 |
| Earnings Date | Apr 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 340.54 |
- Motley Fool•15 hours ago
Everything You Need to Know About Investing in Healthcare
The global demand for healthcare products and services will keep growing significantly. Here's your complete guide to finding the best healthcare stocks and ETFs.
- Zacks•2 days ago
3 Medical Product Stocks Set to Beat This Earnings Season
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
- Motley Fool•2 days ago
Illumina Reports Its Q1 Results on Thursday: 3 Things You Can Expect
The gene-sequencing pioneer isn't likely to hit a home run in Q1. But Illumina should run up the score later in 2019.
- Motley Fool•5 days ago
Pump the Brakes on the Illumina and Pacific Biosciences Deal
The United Kingdom's Competition and Markets Authority has opened an investigation into the acquisition. What happens now?
- Motley Fool•6 days ago
Top Gene-Sequencing Stocks for 2019
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
- Motley Fool•6 days ago
5 Top Healthcare Stocks to Buy in 2019
Healthcare is hot, and these top healthcare stocks could be among the hottest of them all this year.
- Simply Wall St.•6 days ago
Are Insiders Selling Illumina, Inc. (NASDAQ:ILMN) Stock?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak perf...
- Zacks•7 days ago
Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool•8 days ago
3 Top Healthcare Stocks to Buy in April
GW Pharmaceuticals, Illumina, and Intercept Pharmaceuticals could all be great buys this month.
- Zacks•9 days ago
Will Solid Consumables Drive Illumina's (ILMN) Q1 Earnings?
Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.
- ETF Trends•10 days ago
Four Companies Could Power The New Genomics ETF
Earlier this week, the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted, giving investors a new avenue for tapping the fast-growing genomics market. GNOM tracks the Solactive Genomics Index ...
- GuruFocus.com•13 days ago
Get 40% Annualized Returns With This Merger Arbitrage Stock
Illumina Inc. is acquiring Pacific Biosciences for $8 per share in cash. Now trading at just $7.30 a piece, this looks like an attractive arbitrage opportunity
- Zacks•13 days ago
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Zacks•14 days ago
Biotechnology Market on a Tear: 5 ETFs in Spotlight
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
- Zacks•15 days ago
Global X Launches GNOM ETF to Tap Booming Genomics Space
Having exposure to trending areas like Robotics & AI, e-commerce and IoT, Global X is set to gain from the booming genomics market with the GNOM ETF.
- Business Wire•16 days ago
Illumina to Announce First Quarter 2019 Financial Results on Thursday, April 25, 2019
Illumina, Inc. (ILMN) today announced that it will issue results for first quarter 2019 following the close of market on Thursday, April 25, 2019. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s website under the “company” tab at www.illumina.com.
- Investopedia•16 days ago
These Cannabis and China ETFs are Leading the 2019 Rally
Stock investors seeking even bigger returns than the 2019 bull rally might look at five ETFs that have already gained at least 40% year-to-date, approaching triple the 15% pace of the S&P 500. The winners ...
- Motley Fool•16 days ago
Why Vertex Pharmaceuticals Could Conceivably Succeed Too Well
The sky is the limit for this biotech leader.
- Markit•16 days ago
See what the IHS Markit Score report has to say about Illumina Inc.
Illumina Inc NASDAQ/NGS:ILMNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ILMN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ILMN are favorable with net inflows of $113.61 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•16 days ago
Why Illumina Could Be a Health Tech Powerhouse for Your Portfolio
The sky is the limit for the leader in DNA sequencing.
- Motley Fool•16 days ago
5 Stocks in the Age of Miracles
Motley Fool co-founder David Gardner shares five picks that are changing the world and bringing tomorrow closer to today.
- Zacks•17 days ago
Medtronic's New Data for HVAD System to Boost CRHF Segment
Medtronic's (MDT) latest data is expected to boost top-line contributions from the HeartWare HVAD System within the CRHF suite.
- Motley Fool•18 days ago
3 High-Growth Genomics Stocks You Can Buy
These fast-growing companies are leveraging advances in genetic insight in ways that could pay off big for investors.
- Zacks•21 days ago
Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake
The recent development will help Myriad Genetics (MYGN) to boost top-line contributions from prenatal tests.
- CNBC•20 days ago
Final Trades: Illumina, Baidu, Adient & Enterprise Products
The "Halftime Report" traders give their top stocks to watch.
